echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Br J Cancer: Autoimmunity induced by immune checkpoint blocking therapy is related to the prognosis of metastatic melanoma and a unique T cell expression profile

    Br J Cancer: Autoimmunity induced by immune checkpoint blocking therapy is related to the prognosis of metastatic melanoma and a unique T cell expression profile

    • Last Update: 2021-03-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Immune Checkpoint Blocking (ICB) therapy is a type of treatment that mediates T cell activity to increase the anti- tumor immune response.
    It has been used in the treatment of metastatic melanoma (MM).
    Current ICB standard treatment strategies include anti-PD1 monotherapy (nivolumab or pembrolizumab, sICB) or anti-CTLA-4/anti-PD1 (ipilimumab and nivolumab, cICB) combination therapy.

    Immune Checkpoint Blocking (ICB) therapy is a type of treatment that mediates T cell activity to increase the anti- tumor immune response.
    Immune Checkpoint Blocking (ICB) therapy is a type of treatment that mediates T cell activity to increase the anti- tumor immune response.
    ImmuneTumor Immunity

    ICB can activate CD8+ T cells, which in turn causes resistance and immune-related adverse reactions (irAEs).
    However, the relationship between irAEs and baseline parameters and clinical outcomes is unclear.

    The relationship between irAEs and baseline parameters and clinical outcomes is unclear.
    The relationship between irAEs and baseline parameters and clinical outcomes is unclear.

    The purpose of this study was to retrospectively evaluate the survival of irAEs and patients in independent cohorts of patients with metastatic melanoma who received monotherapy or combination therapy (N=144) and secondary (N=211).
    The RNA from CD8+ T cells before and after treatment was sequenced, and the expression of differential genes was evaluated according to the irAE situation.

    The purpose of this study was to retrospectively evaluate the survival of irAEs and patients in independent cohorts of patients with metastatic melanoma who received monotherapy or combination therapy (N=144) and secondary (N=211).
    The purpose of this study was to retrospectively evaluate the survival of irAEs and patients in independent cohorts of patients with metastatic melanoma who received monotherapy or combination therapy (N=144) and secondary (N=211).

    Kaplan-Meier curve analysis of overall survival (OS) and progression-free survival (PFS) of patients

    The results showed that 58.
    3% of patients had early irAE, which was related to longer progression-free (PFS) and overall survival (OS) in the two cohorts.
    The median survival of patients without irAEs was 16.
    6 months.

    The expression of different genes in CD8+ T cells

    The number of monocytes and neutrophils before treatment, rather than BMI value, is a supplementary predictor of the patient's clinical outcome.
    According to the occurrence of irAE, the researchers observed the differential expression of many gene pathway members in CD8+ T cells.
    In patients without irAE, the expression level of CXCR1 was up-regulated before and after treatment.


    All in all, the results of this study show that the early occurrence of irAE after ICB treatment is related to the better survival of MM patients.


    The occurrence of irAEs is related to the expression of many gene pathways, which indicates that irAE can partly reflect the activation of baseline immunity.




    org/10.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.